Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Radiology
Published in: Pediatric Radiology 7/2020

01-06-2020 | Neuroblastoma | Review

Pediatric applications of Dotatate: early diagnostic and therapeutic experience

Authors: Kevin M. McElroy, Larry A. Binkovitz, Andrew T. Trout, Michael R. Czachowski, Victor J. Seghers, Aida N. Lteif, Lisa J. States

Published in: Pediatric Radiology | Issue 7/2020

Login to get access

Abstract

In recent years, new somatostatin receptor agents (SSTRs) have become available for diagnostic imaging and therapy in neuroendocrine tumors. The novel SSTR ligand DOTA-DPhel-Tyr3-octreotate (Dotatate) in particular can be linked with 68Gallium for diagnostic imaging purposes, and with the β-emitter 177Lutetium for radiotherapy in the setting of neuroendocrine tumors. Dotatate imaging offers distinct advantages in the evaluation of neuroendocrine tumors compared to standard techniques, including greater target-to-background ratio and lesion conspicuity, high sensitivity/specificity, improved spatial resolution with positron emission tomography (PET)/CT or PET/MR, and decreased radiation exposure. Although currently off-label in pediatrics, Dotatate theranostics in children are being explored, most notably in the setting of neuroblastoma and hereditary neuroendocrine syndromes. This article provides a multicenter case series of Dotatate imaging and therapy in pediatric patients in order to highlight the spectrum of potential clinical applications.
Literature
1.
2.
Virgolini I, Ambrosini V, Bomanji J et al (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004–2010PubMedCrossRef
3.
4.
Zaknun J, Bodei L, Mueller-Brand J et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 40:800–816PubMedPubMedCentralCrossRef
5.
Alexander N, Vali R, Ahmadzadehfar H et al (2018) Review: the role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma. Curr Radiopharm 11:14–21PubMedCrossRef
6.
Kruhlich L, Dhariwal A, McCann S (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783–790CrossRef
7.
Mojtahedi A, Thamake S, Tworowska I et al (2014) The value of 68Ga-Dotatate PET-CT in diagnosis and management of neuroendocrine tumors compared to FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 4:426–434PubMedPubMedCentral
8.
Krenning E, Kwekkeboom D, Bakker W et al (1993) Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)- and (123ITyr3)-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 20:716–731PubMedCrossRef
9.
Albers A, O’Dorisioa S, Balstera D et al (2000) Somatostatin receptor gene expression in neuroblastoma. Regul Pept 88:61–73PubMedCrossRef
10.
Pauwels E, Cleeren F, Bormans G, Deroose C (2018) Somatostatin receptor PET ligands — the next generation for clinical practice. Am J Nucl Med Mol Imaging 8:311–331PubMedPubMedCentral
11.
Hofman M, Kong G, Neels O et al (2012) High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 56:40–47PubMedCrossRef
12.
Srirajaskanthan R, Kayani I, Quigley A et al (2010) The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51:875–882PubMedCrossRef
13.
Maurice J, Troke R, Win Z et al (2012) A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1266–1270PubMedCrossRef
14.
Naji M, Zhao C, Welsh S et al (2011) 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 13:769–775PubMedCrossRef
15.
Hartmann H, Zophel K, Freudenberg R et al (2009) Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedzin 48:201–207CrossRef
16.
Hofman M, Lau W, Hicks R (2015) Somatostatin receptor imaging with 68Ga Dotatate PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516PubMedCrossRef
17.
Krenning E, Bakker W, Breeman W et al (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244PubMedCrossRef
18.
Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw 13:78–108CrossRef
19.
Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335–1342PubMedPubMedCentralCrossRef
20.
21.
Loh K, Waser B, Tan L et al (2002) Somatostatin receptors in nasopharyngeal carcinoma. Virchows Arch 441:444–448PubMedCrossRef
22.
Heck J, Ritz B, Hung R et al (2008) The epidemiology of neuroblastoma. Paediatr Perinat Epidemiol 23:125–143CrossRef
23.
Mueller W, Coppenrath E, Pfluger T (2013) Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol 43:418–427PubMedCrossRef
24.
25.
Dumba M, Jawad N, McHugh K (2015) Neuroblastoma and nephroblastoma: a radiological review. Cancer Imaging 15:1–14CrossRef
26.
Sharp S, Trout A, Weiss B, Gelfand M (2016) MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 36:258–278PubMedCrossRef
27.
Hofman M, Hicks R (2012) Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med 14:71–81PubMed
28.
Kroiss A, Putzer D, Uprimny C et al (2011) Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 38:865–873PubMedCrossRef
29.
Kong G, Hofman M, Murray W et al (2016) Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol 38:87–96PubMedCrossRef
30.
31.
Goel R, Shukla J, Bansal D et al (2014) 68Ga-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors. Indian J Nucl Med 29:13–17PubMedPubMedCentralCrossRef
32.
Fiani B, Quadri S, Cathel A et al (2019) Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options. World Neurosurg 126:194–211PubMedCrossRef
33.
Sheehan J, Payne R (2016) Esthesioneuroblastomas. In: Winn H (ed) Youmans and Winn neurological surgery e-book. Elsevier Health Sciences, New York, pp 1284–1292
34.
Czapiewski P, Kunc M, Gorczynski A et al (2018) Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature. Hum Pathol 79:144–150PubMedCrossRef
35.
Bosman F, Carneiro F, Hruban R et al (2010) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon
36.
Vlajkovic M, Rajic M, Stevic M et al (2012) Clinical role of somatostatin analogues scintigraphy in patients with carcinoid tumors. J Nucl Med 53:2113
37.
Broaddus R, Herzog C, Hicks M (2003) Neuroendocrine tumors (carcinoids and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med 127:1200–1203PubMed
38.
Parkes S, Muir K, Al Sheyyab M et al (1993) Carcinoid tumors of the appendix in children 1957-1986: incidence, treatment and outcome. Br J Surg 80:502–504PubMedCrossRef
39.
Schembri G, Hain S, Roach P (2015) Value of Gallium-68 Dotatate PET scan in staging patients with appendiceal carcinoid tumour: a case series. J Nucl Med 56:1660
40.
Granberg D, Sundin A, Janson E et al (2003) Octreoscan in patients with bronchial carcinoid tumors. Clin Endocrinol 59:793–799CrossRef
41.
Yellin A, Zwas S, Rozenman J et al (2005) Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. Isr Med Assoc J 7:712–716PubMed
42.
Musi M, Carbone R, Bertocci C et al (1988) Bronchial carcinoid tumours: a study on clinicopathologic features and role of octreotide scintigraphy. Lung Cancer 22:97–102CrossRef
43.
Lococo F, Cesario A, Paci M et al (2014) PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumor Biol 35:8369–8377CrossRef
44.
Tan T, Hussein Z, Saad F, Shuaib I (2015) Diagnostic performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl Med Mol Imaging 49:143–151PubMedPubMedCentralCrossRef
45.
Chang C, Pattison D, Tothill R et al (2016) 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging 16:22PubMedPubMedCentralCrossRef
46.
Jha A, Ling A, Millo C et al (2018) Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45:787–797PubMedCrossRef
47.
Thakker R, Newey P, Walls G et al (2012) Clinical practice guidelines for multiple endocrine neoplasia Type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011PubMedCrossRef
48.
49.
Brandi M, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 86:5658–5671PubMedCrossRef
50.
51.
Wohlk N, Schweizer H, Erlic Z et al (2010) Multiple endocrine neoplasia Type 2. Best Pract Res Clin Endocrinol Metab 24:371–387CrossRef
52.
Asgharian B, Chen Y, Patronas N et al (2004) Meningiomas may be a component tumor of multiple endocrine neoplasia Type 1. Clin Cancer Res 10:869–880PubMedCrossRef
53.
Thakker R (2010) Multiple endocrine neoplasia Type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370PubMedCrossRef
54.
Trouillas J, Labat-Moleur F, Sturm N et al (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia Type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2,509 non-MEN1 patients. Am J Surg Pathol 32:534–543PubMedCrossRef
55.
Gibril F, Venzon D, Ojeaburu J et al (2001) Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86:5282–5293PubMedCrossRef
56.
Thomas-Marques L, Murat A, Delemer B et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia Type 1. Am J Gastroenterol 101:266–273PubMedCrossRef
57.
Kann P, Balakina E, Ivan D et al (2006) Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia Type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 13:1195–1202PubMedCrossRef
58.
Verges B, Boureille F, Goudet P et al (2002) Pituitary disease in MEN Type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465PubMedCrossRef
59.
Lefebvre M, Foulkes W (2014) Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol 21:8–17CrossRef
60.
Scarsbrook A, Thakker R, Wass J et al (2006) Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics 26:433–451PubMedCrossRef
61.
Skinner M, DeBenedetti M, Moley J et al (1996) Medullary thyroid carcinoma in children with multiple endocrine neoplasia Types 2A and 2B. J Pediatr Surg 31:177–181PubMedCrossRef
62.
Brauckhoff M, Machens A, Hess S et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044–1050PubMedCrossRef
63.
Rednam S, Erez A, Druker H et al (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23:e68–e75PubMedCrossRef
64.
65.
66.
Lenders J, Duh Q, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942PubMedCrossRef
67.
Hes F, Feldberg M (1999) Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses). Eur Radiol 9:598–610PubMedCrossRef
68.
69.
Leung R, Biswas S, Duncan M, Rankin S (2008) Imaging features of von Hippel-Lindau disease. Radiographics 28:65–79PubMedCrossRef
70.
Karsdorp N, Elderson A, Wittebol-Post D et al (1994) Von Hippel Lindau disease: new strategies in early detection and treatment. Am J Med 97:158–168PubMedCrossRef
71.
Taouli B, Ghouadni M, Corréas J et al (2003) Spectrum of abdominal imaging findings in von Hippel-Lindau disease. AJR Am J Roentgenol 181:1049–1054PubMedCrossRef
72.
73.
Williams V, Lucas J, Babcock M et al (2009) Neurofibromatosis Type 1 revisited. Pediatrics 123:124–133CrossRefPubMed
74.
Friedman J, Arbiser J, Epstein J et al (2002) Cardiovascular disease in Neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genitourin Med 4:105–111CrossRef
75.
Howe J, Norton J, Wells S (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia Type 2A: results of long-term follow-up. Surgery 114:1070–1077PubMed
76.
77.
Alrezk R, Suarez A, Tena I, Pacak K (2018) Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging. Front Endocrinol 9:515CrossRef
78.
Tufton N, Sahdev A, Akker S (2017) Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 1:897–907PubMedPubMedCentralCrossRef
79.
Mukherjee A, Karunanithi S, Bal C, Kumar R (2014) 68Ga DOTANOC PET/CT aiding in the diagnosis of Von Hippel-Lindau syndrome by detecting cerebellar hemangioblastoma and adrenal pheochromocytoma. Clin Nucl Med 39:920–921PubMedCrossRef
80.
Prasad V, Tiling N, Denecke T et al (2016) Potential role of 68Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Eur J Nucl Med Mol Imaging 43:2014–2020PubMedCrossRef
81.
Papadakis G, Millo C, Jassel I et al (2017) 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau disease-associated retinal hemangioblastoma. Clin Nucl Med 42:189–190PubMedCrossRef
82.
Papadakis G, Millo C, Sadowski S et al (2016) Kidney tumor in a von Hippel-Lindau (VHL) patient with intensely increased activity on 68Ga-DOTA-TATE PET/CT. Clin Nucl Med 41:970–971PubMedPubMedCentralCrossRef
83.
Stewart D, Korf B, Nathanson K et al (2018) Care of adults with neurofibromatosis Type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 20:671–682PubMedCrossRef
84.
Strosberg J, Wolin E, Chasen B et al (2016) NETTER-1 Phase III in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE: efficacy and safety results. J Nucl Med 57:629
85.
Bleeker G, Tygat G, Adam J et al (2015) 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev 9:CD009263
86.
Gains J, Bomanji J, Fersht N et al (2011) 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med 52:1041–1047PubMedCrossRef
87.
Menda Y, O'Dorisio M, Kao S et al (2010) Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 51:1524–1531PubMedCrossRef
88.
Zhu W, Zhang J, Singh A et al (2019) Metastatic nasopharyngeal carcinoma treated with intraarterial combined with intravenous peptide receptor radionuclide therapy. Clin Nucl Med 44:989–990PubMedCrossRef
Metadata
Title
Pediatric applications of Dotatate: early diagnostic and therapeutic experience
Authors
Kevin M. McElroy
Larry A. Binkovitz
Andrew T. Trout
Michael R. Czachowski
Victor J. Seghers
Aida N. Lteif
Lisa J. States
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Radiology / Issue 7/2020
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-020-04688-z

Other articles of this Issue 7/2020

Pediatric Radiology 7/2020 Go to the issue

Original Article

The fetal falx cerebelli

Pictorial Essay

Imaging of cerebral complications of extracorporeal membrane oxygenation in infants with congenital heart disease — ultrasound with multimodality correlation

Case Report

Transpubic variant of congenital prepubic sinus on magnetic resonance imaging

Original Article

Normal FDG uptake in the adenoids and palatine tonsils in children on PET/MRI

Letter to the Editor

Computed tomography of the lungs in novel corona virus (COVID-19) infection

Commentary

Wellness in pediatric radiology: lessons learned in a time of pandemic